Receptor of advanced glycation end products and cardiovascular risk in elderly with type 2 diabetes mellitus


Submitted: December 12, 2016
Accepted: July 18, 2017
Published: February 12, 2018
Abstract Views: 957
PDF: 379
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Claudia Borsa Ana Aslan - National Institute of Gerontology and Geriatrics, Bucharest, Romania.
  • Daniela Gradinaru Carol Davila - University of Medicine and Pharmacy, Department of Biochemistry, Bucharest, Romania.
  • Denisa Margina Carol Davila - University of Medicine and Pharmacy, Department of Biochemistry, Bucharest, Romania.
  • Gabriel Ioan Prada Ana Aslan - National Institute of Gerontology and Geriatrics, Bucharest, Romania.
  • Catalina Pena Ana Aslan - National Institute of Gerontology and Geriatrics, Bucharest, Romania.
The interaction of Advanced Glycation End products (AGEs) and their specific receptor, Receptor for Advanced Glycation End products (RAGE) play an important role in diabetes and vascular complications. Engagement of RAGE by AGEs leads to activation of cellular signaling pathways and vascular dysfunction. The soluble RAGE (sRAGE) acts as a decoy receptor for AGEs. The aim of this study was to evaluate the soluble RAGE in elderly subjects with T2DM and its relationships with glycoxidative, inflammatory and cardiovascular risk markers. The serum AGEs, sRAGE, interleukine- 6 (IL-6), lipid profile, glycemic status, uric acid, creatinine and cardiovascular risk markers were determined in elderly subjects with type 2 diabetes mellitus (T2DM, N=72, 75±4 years old) and aged-match healthy subjects (N=15, 76±3 years old). Significant higher levels of AGEs and AGEs/sRAGE ratio concomitantly with significant lower levels of sRAGE were pointed out in elderly subjects with T2DM as compared to control. The values of AGEs/sRAGE ratio were significantly positively associated (P<0.05) with atherogenic, inflammatory and cardiovascular risk markers and significantly negatively with anti-atherogenic lipoproteins (P<0.05). The multivariate regression analyses showed that atherogenic index was an independent predictor of sRAGE levels and AGEs/sRAGE ratio values. The associations of soluble RAGE and the AGEs/sRAGE ratio with atherogenic and inflammatory markers could reflect the protective role of soluble variants of RAGE in atherosclerosis and diabetes vascular complications.

Borsa, C., Gradinaru, D., Margina, D., Prada, G. I., & Pena, C. (2018). Receptor of advanced glycation end products and cardiovascular risk in elderly with type 2 diabetes mellitus. Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale, 90(2). https://doi.org/10.4081/jbr.2017.6462

Downloads

Download data is not yet available.

Citations